amgen

JP Morgan has raised the price target on Amgen (NASDAQ: AMGN) from $65 to $70 and maintains its Overweight rating.

Stifel Nicolaus is lowering its PT on shares of Amgen Inc. (NASDAQ: AMGN) from $70 to $68. Amgen closed Thursday at $53.69.

Jefferies is providing an update from Amgen Inc.'s (NASDAQ: AMGN) business review meeting. “At its inexpensive valuation (trading at ~10x estimated '11 earnings similar to big pharma vs. peers ~14x), we view strong execution (ESA franchise stabilization, Prolia uptick, strong XGEVA launch) will...

According to Jefferies, Amgen (NASDAQ: AMGN) saw a slight 1Q EPS beat. Jefferies said that Slight beat on 1Q top- and bottom-line but mix of good and bad (encouraging XGEVA sales, but disappointing Epogen sales; higher OpEx, but lower tax rate benefit). “AMGN maintains FY11 guidance and to detail...

According to Piper Jaffray, Amgen (NASDAQ: AMGN) 1Q earnings are mixed. Piper Jaffray said that it remains buyers of AMGN after a mixed 1Q11 earnings report, which featured strong Xgeva sales offset by weak Prolia and Epogen sales. “1Q11 confirmed our expectation for a more modest market...

Piper Jaffray has lowered the price target on Amgen (NASDAQ: AMGN) from $73 to $72 and maintains its Overweight rating.

JP Morgan has published a research report on Amgen, Inc. (NASDAQ: AMGN) commenting on investor concerns over CMS's National Coverage Distribution (NCD) on ESA reimbursements for dialysis patients. In the report, JP Morgan writes "The bottom line is that the decision memo recommends not issuing an...

Goldman Sachs has published a research report on Amgen, Inc. (NASDAQ: AMGN) after the company saw relief from unchanged ESA reimbursements. In the report, Goldman Sachs writes "While we see some near term relief, we maintain our Sell rating as we do not see room for sustainable upside. We remain...

Deutsche Bank has issued a report predicting April 21 to be a positive catalyst for Amgen (NYSE: AMGN) shares. According to Deutsche Bank, "We maintain our HOLD rating of Amgen shares (TP $56) as we see limited opportunity for growth. Sales of Amgen's Xgeva are offsetting declines in the co's Epo...

In a report published by Jefferies, Amgen (NASDAQ: AMGN) is seeing no NCD proposal for ESAs. Jefferies said that CMS proposes no national coverage determination (NCD) for ESAs in patients with CKD at this time, in line with its expectation from its reimbursement expert discussion (note published...

Deutsche Bank is out with its report today on Amgen (NASDAQ: AMGN), maintaining Hold. In a note to clients, Deutsche Bank writes, "We maintain our Hold rating on Amgen (TP $56) as we see limited opportunity for growth. The key investor controversy is what Amgen will do with its cash (~17.4B as of...

In a report published by Piper Jaffray, Amgen (NASDAQ: AMGN) shares have come under pressure ahead of a proposed National Coverage Determination (NCD, March 16) that could further limit use of Epogen/Aranesp in pre-dialysis and dialysis patients, despite clear lack of clinical data supporting the...

Deutsche Bank is out with its report today on Amgen (NASDAQ: AMGN), maintaining Hold. In a note to clients, Deutsche Bank writes, "We maintain our HOLD rating of Amgen shares (TP $56) as we see limited opportunity for growth. Sales of Amgen's Xgeva are offsetting declines in the co's Epo biz. We...

J.P. Morgan is out with its report today on Amgen (NASDAQ: AMGN), maintaining Overweight. In a note to clients, J.P. Morgan writes, "Given low expectations for legacy products, and our bullish view on the denosumab franchise, and the burgeoning pipeline, we are maintaining our Overweight rating on...

Oppenheimer has published a research report on Amgen, Inc. (NASDAQ: AMGN) after the company reported in-line 4Q results on 1/24. In the report, Oppenheimer writes "On 1/24, AMGN reported in-line 4Q revenue of $3.84B and adjusted EPS of $1.17 vs. $1.11 cons, driven by share repurchases/lower taxes....